From Prostate Cancer Foundation:
Is one of these tests right for you? Do you even need one?
Read more about it HERE
Molecular Biomarker Tests for Localized Prostate Cancer
Advanced Prostate Cancer Consensus Conference 2019 Videos
URO Today has published a collection of videos from the APCC 2019 conference. This informative collection of 60 short videos cover a wide range of prostate cancer topics. You can view the video collection on URO Today HERE
More Than One Prostate Cancer in a Single Prostate?
As many as 40% of newly diagnosed PCa patients have unifocal disease, that is, just one focus of cancer. But that still leaves 60-80% of patients with multifocal PCa. Without evidence to the contrary, multiple foci in the same gland were thought to be biologically homogeneous, that is, identical to each other.
Then, along came the tools to analyze PCa at the molecular level, bringing new knowledge of the biology of PCa.
Read about this by clicking here.
Genetics & Genomic Testing – UsTOO
While not appropriate for every prostate cancer patient, genomic testing can provide a man and his care team with valuable information at various stages of disease management specific to whether the cancer is likely to be aggressive or indolent, thereby helping him to make an informed decision on how to best address his prostate cancer.
Read more about Genetics vs. Genomics, Tools and Tests available here
2018 Genitourinary Cancers Symposium – Proceedings on Prostate Cancer
The 2018 Genitourinary Cancers Symposium event featured groundbreaking research among members of the cancer care and research community who diagnose, treat, and study genitourinary malignancies.
Click on the below links to view conference proceedings on
PCF’s 2017 State of the Science Report
Highlights and summary from the 24th Annual PCF Scientific Retreat on October 2017. Read the report here.
FDA Approves Foundation Medicine’s FoundationOne CDx Comprehensive Genomic Profiling Test
FDA has approved the FoundationOne CDx (F1CDx) cancer biomarker assay concurrently with a decision from the Centers for Medicare & Medicaid Services (CMS) to provide insurance coverage for the next-generation sequencing (NGS)-based in vitro diagnostic (IVD) test.
FDA Approves Foundation Medicine’s FoundationOne CDx™, the First and Only Comprehensive Genomic Profiling Test for All Solid Tumors Incorporating Multiple Companion Diagnostics.
Read more about it here
US Too Prostate Cancer Panel Discussion and Webcast on Advanced Prostate Cancer
US Too Prostate Cancer Panel Discussion and Webcast on Advanced Prostate Cancer
- Presented by: Bayer
- Sponsored by: Dendreon and Jannsen Oncology
- In Kind Sponsor: Los Padres
- Guest Speakers:
- Dr. Edwin Morales – Urology Specialist, San Antonio
- Dr. Michael Liss – Urologist, Urologic Oncologist, and Lead Prostate Cancer Researcher at UT Health, San Antonio
- Dr. Vijay K. Gunuganti – Medical Oncologist at Texas Oncology
- Moderator: Dr. Juan A. Reyna – Staff Physician at Audie L. Murphy Memorial VA Hospital; and Clinical Faculty at UT Health
Watch the recording here
FDA approves first cancer treatment for any solid tumor with a specific genetic feature
The U.S. Food and Drug Administration today granted accelerated approval to a treatment for patients whose cancers have a specific genetic feature (biomarker). This is the first time the agency has approved a cancer treatment based on a common biomarker rather than the location in the body where the tumor originated.
Read more on fda.gov
Genomic Testing in Cancer Treatment
Genomic testing is done on cancerous tissue taken from the prostate in order to provide information about how your prostate cancer might behave. By looking at the genetic makeup of the cancer, these tests may help predict whether your prostate cancer grows slowly or aggressively.
Genomic testing can be performed on both biopsy tissue and on tissue from an entire prostate following a prostatectomy.